come first served: Live & Latest News Updates : Vimarsana.com

Web Review, Week 2024-17

Website Description

Central Bureau Of Investigation vs A Raja & Ors on 22 March, 2024

VCIA Annual Conference coming August 7-10 | Vermont Business Magazine

SPCA Of North Texas says many are struggling to feed pets

According to the SPCA of Texas, almost 20% of Fort Worth families may have a hard time getting food for themselves, let alone their pets.

Qatar 2022 Marketing Director: Sales phase golden opportunity for ticket purchases

Doha:Executive Director of Sales, Marketing and Communication in FIFA World Cup 2022 Hassan Rabia Al Kuwari said a few hours prior to the commencement...

DRDO invites Express of Interest for bulk production of COVID drug 2-DG

New Delhi [India], June 9 (ANI): The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production.

DRDO To Transfer Technology Of Anti-COVID Drug '2-DG' To India Pharma Firms, Invites EoI

DRDO To Transfer Technology Of Anti-COVID Drug '2-DG' To India Pharma Firms, Invites EoI by Swarajya Staff - Jun 9, 2021 07:25 AM DRDO Logo (Pic Via Wikipedia) The Defence Research and Development Organisation (DRDO) has sought Expression of Interest (EoI) for transfer of technology for bulk manufacturing of the 2-Deoxy-D-Glucose (2-DG), a drug developed by the DRDO for treatment of Covid-19 patients. The drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the DRDO, in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad. 2-DG is a glucose analogue, which has the 2-hydroxyl group replaced by hydrogen. The molecule is transported in cells by the glucose transporters on the cell membrane but it cannot undergo further glycolysis and act as inhibitor of glycolysis. Therefore, cells with higher glucose uptake, for example tumor cells, virally infected cells, inflammatory cells have also a higher uptake of 2-DG.

DRDO invites expression of interest for bulk production of Covid drug 2-DG

Read more about DRDO invites expression of interest for bulk production of Covid drug 2-DG on Business Standard. The 2-DG is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy' Laboratories.